Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
Supernus Pharmaceuticals Inc (NASDAQ: SUPN) closed the day trading at $46.98 up 2.04% from the previous closing price of $46.04. In other words, the price has increased by $2.04 from its previous closing price. On the day, 0.68 million shares were traded. SUPN stock price reached its highest trading level at $47.07 during the session, while it also had its lowest trading level at $45.7601.
Ratios:
For a better understanding of SUPN, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.04 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.17. For the most recent quarter (mrq), Quick Ratio is recorded 2.43 and its Current Ratio is at 2.58. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
On February 19, 2025, Cantor Fitzgerald Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $57 to $36. On January 06, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $57.Cantor Fitzgerald initiated its Overweight rating on January 06, 2025, with a $57 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 22 ’25 when JACK A KHATTAR bought 16,587 shares for $46.04 per share.
Mottola Frank sold 5,000 shares of SUPN for $229,350 on Sep 12 ’25. The SVP, Chief Tech. Ops. Officer now owns 15,496 shares after completing the transaction at $45.87 per share. On Sep 12 ’25, another insider, FRANK MOTTOLA, who serves as the Officer of the company, bought 5,000 shares for $45.87 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SUPN now has a Market Capitalization of 2634313728 and an Enterprise Value of 2143491712. As of this moment, Supernus’s Price-to-Earnings (P/E) ratio for their current fiscal year is 41.06, and their Forward P/E ratio for the next fiscal year is 19.28. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 6.11. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.96 while its Price-to-Book (P/B) ratio in mrq is 2.48. Its current Enterprise Value per Revenue stands at 3.223 whereas that against EBITDA is 16.211.
Stock Price History:
The Beta on a monthly basis for SUPN is 0.78, which has changed by 0.53680074 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, SUPN has reached a high of $46.78, while it has fallen to a 52-week low of $29.16. The 50-Day Moving Average of the stock is 15.40%, while the 200-Day Moving Average is calculated to be 31.69%.
Shares Statistics:
Over the past 3-months, SUPN traded about 830.08K shares per day on average, while over the past 10 days, SUPN traded about 749360 shares per day. A total of 56.12M shares are outstanding, with a floating share count of 52.90M. Insiders hold about 5.66% of the company’s shares, while institutions hold 106.16% stake in the company. Shares short for SUPN as of 1756425600 were 4801288 with a Short Ratio of 5.78, compared to 1753920000 on 5080993. Therefore, it implies a Short% of Shares Outstanding of 4801288 and a Short% of Float of 12.2.
Earnings Estimates
The company has 3.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $0.59, with high estimates of $0.62 and low estimates of $0.56.
Analysts are recommending an EPS of between $2.31 and $2.16 for the fiscal current year, implying an average EPS of $2.22. EPS for the following year is $2.44, with 3.0 analysts recommending between $2.69 and $2.15.
Revenue Estimates
5 analysts predict $175.82M in revenue for the current quarter. It ranges from a high estimate of $183.2M to a low estimate of $161M. As of the current estimate, Supernus Pharmaceuticals Inc’s year-ago sales were $175.69MFor the next quarter, 5 analysts are estimating revenue of $198.52M. There is a high estimate of $208.7M for the next quarter, whereas the lowest estimate is $181.8M.
A total of 5 analysts have provided revenue estimates for SUPN’s current fiscal year. The highest revenue estimate was $697.99M, while the lowest revenue estimate was $671.4M, resulting in an average revenue estimate of $689.62M. In the same quarter a year ago, actual revenue was $661.82MBased on 5 analysts’ estimates, the company’s revenue will be $814.79M in the next fiscal year. The high estimate is $843.84M and the low estimate is $734.5M.
